• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Bioenvision to Hold Fiscal 2007 Year-End Financial Results Conference Call Wednesday, September 12, 2007

Posted on: Wednesday, 5 September 2007, 18:03 CDT

Bioenvision, Inc. (Nasdaq:BIVN) will hold a live webcast of its quarterly conference call at 10:00 a.m. (EDT) on Wednesday, September 12, 2007. Jim Scibetta, chief financial officer, will host the call. Senior management will discuss the Company's financial results and recent developments for the fiscal year ended June 30, 2007. Bioenvision will announce the highlights of these topics in a press release to be issued before the market opens on September 12, 2007, prior to the conference call.

The live conference call and webcast can be accessed with the following information.

Live Toll Free Number (US & Canada): 866-585-6398 Live International Number: 416-849-9626 Webcast: www.bioenvision.com

A replay of the call and webcast will be available for 14 days and can be accessed with the following information.

Replay Toll Free Number (US & Canada): 866-245-6755 Replay International Number: 416-915-1035 Replay Passcode: 375872 Webcast Replay: www.bioenvision.com

About Bioenvision

Bioenvision's primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision's product pipeline is focused on: Evoltra® and Modrenal®. For more information on Bioenvision please visit our website at www.bioenvision.com.

Certain statements contained in this press release are "forward-looking" statements, including express or implied statements regarding Bioenvision obtaining regulatory approval of its products and Bioenvision's ability to deliver the additional data requested by the EMeA. Because these statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with whether the merger of Wichita Bio Corporation with and into Bioenvision will be approved by the stockholders of Bioenvision; risks associated with the uncertainty as to whether such merger will in fact occur, risks associated with disruptions from the proposed merger transaction which may harm relationships with customers, employees, suppliers and partners; risks associated with the outcome of litigation and regulatory proceedings to which we are currently a party and may become a party in the future; risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law and the statements contained in this press release are current as of the date of this release only.

Source: Business Wire

More News in this Category